There are currently many custom/academic or commercial BRCA1/2 target panels that have been established in recent years because of investigations on the use and impact of NGS in breast/ovarian cancer [56,60,61,62], the majority of which are based on the amplicon sequencing technique. This evidence concerns the gene BRCA1 and ovarian cancer.